Search

Your search keyword '"Liver Cirrhosis virology"' showing total 4,731 results

Search Constraints

Start Over You searched for: Descriptor "Liver Cirrhosis virology" Remove constraint Descriptor: "Liver Cirrhosis virology"
4,731 results on '"Liver Cirrhosis virology"'

Search Results

151. Safe use of livers from deceased donors older than 70 years in recipients with HCV cirrhosis treated with direct-action antivirals. Retrospective cohort study.

152. Cirrhosis and Severe Acute Respiratory Syndrome Coronavirus 2 Infection in US Veterans: Risk of Infection, Hospitalization, Ventilation, and Mortality.

153. Directly acting antivirals are safe and effective in HCV positive patients aged 80 years and older: a multicenter real-life study.

154. The Landscape of Cell-Free HBV Integrations and Mutations in Cirrhosis and Hepatocellular Carcinoma Patients.

155. Innumerable cerebral microbleeds in hepatitis B virus-related decompensated liver cirrhosis: a case report.

156. A simple noninvasive model to predict significant fibrosis in children with chronic hepatitis B.

157. Reduced Energy Metabolism Impairs T Cell-Dependent B Cell Responses in Patients With Advanced HBV-Related Cirrhosis.

158. Efficacy and safety of danoprevir plus sofosbuvir in GT 1, 2, 3, or 6 chronic hepatitis C patients with or without cirrhosis in China.

159. Analysis of Serum MicroRNA-122 Expression at Different Stages of Chronic Hepatitis B Virus Infection.

160. Clinical significance of small molecule metabolites in the blood of patients with different types of liver injury.

161. Serum potassium levels and prognosis in HBV-associated decompensated cirrhosis.

162. Real-world Effectiveness and Safety of Direct-acting Antiviral Agents in Patients with Chronic Hepatitis C Genotype 2 Infection: Korean Multicenter Study.

163. The combination of the NS5A and cyclophilin inhibitors results in an additive anti-HCV inhibition in humanized mice without development of resistance.

164. Hepatic parenchyma and vascular blood flow changes after TIPS with spectral CT iodine density in HBV-related liver cirrhosis.

165. Prevalence of liver fibrosis and cirrhosis in 699 Moroccan patients with chronic hepatitis C.

166. Modifications of liver stiffness and CXCL4, TGF-β1 and HGF are similar in HCV- and HIV/HCV-infected patients after DAAs.

167. Liver function following hepatitis C virus eradication by direct acting antivirals in patients with liver cirrhosis: data from the PITER cohort.

168. A novel nomogram to predict evident histological liver injury in patients with HBeAg-positive chronic hepatitis B virus infection.

169. Stereotactic radiotherapy for hepatocellular carcinoma induced by hepatitis C and the relationships of changes in carbohydrate antigen 19-9 with AFP and PIVKA-II.

170. Low seroprevalence of SARS-CoV-2 antibodies in cirrhotic patients.

171. HCV Eradication in Primary or Secondary Prevention Optimizes Hepatocellular Carcinoma Curative Management.

172. A non-invasive model for predicting liver fibrosis in HBeAg-positive patients with normal or slightly elevated alanine aminotransferase.

173. Serum midkine is a more sensitive predictor for hepatocellular carcinoma than Dickkopf-1 and alpha-L-fucosidase in cirrhotic HCV patients.

174. Demographics and outcomes of hepatitis B and D: A 10-year retrospective analysis in a Swiss tertiary referral center.

175. Revised Korean Antiviral Guideline Reduces the Hepatitis B-related Hepatocellular Carcinoma Risk in Cirrhotic Patients.

176. Impacts of the Percentage of Basal Core Promoter Mutation on the Progression of Liver Fibrosis After Hepatitis B e Antigen Seroconversion.

177. Rare case of endogenous Klebsiella endophthalmitis associated with emphysematous prostatitis in a patient with diabetes, cirrhosis and COVID-19.

178. Impact of IL10 , MTP , SOD2 , and APOE Gene Polymorphisms on the Severity of Liver Fibrosis Induced by HCV Genotype 4.

179. Predictive Performances of Blood Parameter Ratios for Liver Inflammation and Advanced Liver Fibrosis in Chronic Hepatitis B Infection.

180. Changes in Liver Stiffness and Noninvasive Fibrosis Scores in Egyptian Adolescents Successfully Treated with Ledipasvir-Sofosbuvir for Chronic Hepatitis C Virus Infection.

181. Neutrophil count to albumin ratio as a prognostic indicator for HBV-associated decompensated cirrhosis.

182. Recent Trends in the Global Burden of Hepatitis B Virus: 2007-2017.

183. Patients with chronic hepatitis C receiving treatment with direct acting antivirals: How is this population changing?

184. Liver Pathologic Changes After Direct-Acting Antiviral Agent Therapy and Sustained Virologic Response in the Setting of Chronic Hepatitis C Virus Infection.

185. Fibrosis Regression After Eradication of Hepatitis C Virus: From Bench to Bedside.

186. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment.

187. Transcriptome Classification Reveals Molecular Subgroups in Patients with Hepatitis B Virus.

188. Sofosbuvir-based therapies associated with regression of liver fibrosis in patients with hepatitis C virus infection: A prospective observational study.

189. Study of CXCL9-11 gene polymorphisms in liver fibrosis among patients with chronic hepatitis C.

190. Enhanced immune responses, PI3K/AKT and JAK/STAT signaling pathways following hepatitis C virus eradication by direct-acting antiviral therapy among Egyptian patients: a case control study.

191. A limited role of cytokine storm and fibrogenesis in COVID-19 related liver injury.

192. Effectiveness of 8- and 12-Week Treatment with Ombitasvir/ Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve HCV Patients in a Real-Life Setting in Romania: the AMETHYST Study.

193. A genomic variant of ALPK2 is associated with increased liver fibrosis risk in HIV/HCV coinfected women.

194. Impact of TIPS on Splenic Volume and Thrombocytopenia.

195. Presentation and Outcomes of Hepatocellular Carcinoma in the Arabian Peninsula: A Review of a Single Institution Experience in the Sorafenib Era.

196. Characteristics of patients with hepatitis C virus infection and antiviral treatment initiation in Taiwan: The MOSAIC study.

197. Lipid Droplets Accumulation during Hepatitis C Virus Infection in Cell-Culture Varies among Genotype 1-3 Strains and Does Not Correlate with Virus Replication.

198. Sophisticated viral quasispecies with a genotype-related pattern of mutations in the hepatitis B X gene of HBeAg-ve chronically infected patients.

199. Sunitinib-associated hyperammonemic encephalopathy successfully managed with higher intensity conventional hemodialysis: A case report.

200. Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis.

Catalog

Books, media, physical & digital resources